AbbVie Chooses Two Parkinson’s Therapies to Develop With Mission

AbbVie Chooses Two Parkinson’s Therapies to Develop With Mission

302315

AbbVie Chooses Two Parkinson’s Therapies to Develop With Mission

AbbVie has selected two drug candidates — both targeting enzymes known as DUBs — for further development as possible Parkinson’s disease treatments, as part of the company’s ongoing collaboration with Mission Therapeutics. “We are delighted to have reached this next major milestone in our collaboration with AbbVie and receive the $20 million milestone — this represents a big step forward for Mission and further highlights DUBs as targets for drug development,” Anker Lundemose, MD, PhD,…

You must be logged in to read/download the full post.